FY2025 EPS Estimates for Replimune Group Lowered by Wedbush

Replimune Group, Inc. (NASDAQ:REPL) – Analysts at Wedbush cut their FY2025 earnings per share estimates for Replimune Group in a note issued to investors on Wednesday, February 12th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($3.07) per share for the year, down from their previous estimate of ($2.91). The consensus estimate for Replimune Group’s current full-year earnings is ($2.88) per share. Wedbush also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.85) EPS, Q2 2026 earnings at ($0.76) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.52) EPS and FY2026 earnings at ($2.93) EPS.

Other equities research analysts have also recently issued reports about the company. BMO Capital Markets upped their target price on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Jefferies Financial Group upped their target price on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Finally, HC Wainwright upped their target price on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Replimune Group presently has an average rating of “Buy” and an average price target of $19.29.

Replimune Group Stock Down 1.3 %

NASDAQ REPL opened at $14.10 on Monday. The business has a fifty day moving average price of $12.54 and a two-hundred day moving average price of $11.74. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The stock has a market capitalization of $964.72 million, a PE ratio of -4.62 and a beta of 1.30.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09).

Insider Activity

In other news, CEO Sushil Patel sold 10,000 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares in the company, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Sterling Capital Management LLC raised its position in Replimune Group by 364.5% during the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after purchasing an additional 1,655 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock worth $82,000 after purchasing an additional 5,922 shares during the last quarter. Aster Capital Management DIFC Ltd raised its position in Replimune Group by 8,798.9% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock worth $100,000 after purchasing an additional 8,183 shares during the last quarter. Erste Asset Management GmbH bought a new position in Replimune Group during the 3rd quarter worth $133,000. Finally, XTX Topco Ltd bought a new position in Replimune Group during the 4th quarter worth $137,000. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.